Search for content, post, videos
Advertisement

Aurealis Therapeutics receives PRIME designation from EMA

personalized medicine

The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Aurealis Therapeutics’ lead product candidate AUP-16 for the treatment of non-healing Diabetic Foot Ulcers (nhDFU).

“With the PRIME status and support by EMA, we aim to expedite the further development of AUP-16 program to bring a novel therapeutic option for patients suffering from nhDFU, and bring Aurealis multi-target gene therapies faster to market. This is the result of a fantastic cross-functional collaboration,” says Hanna-Riikka Kärkkäinen, Head of Quality and Regulatory Affairs of Aurealis Therapeutics.

Read more: From theory to therapy: Gene therapy

AUP-16

AUP-16 multi-target gene therapy is a potential first-in-class therapeutic approach which comprises a synergistic combination of four therapeutic components in one pharmaceutical ingredient (API). AUP-16 consists of Lactococcus Cremoris bacterium, genetically engineered to produce, and release three human therapeutic proteins in the wounds: fibroblast growth factor 2 (FGF-2), interleukin 4 (IL-4) and colony stimulating factor 1 (CSF-1). AUP-16 bacterium act as millions of nanoscale bioreactors in the wound, allowing to re-start and accelerate the healing of chronic wounds by 1) awakening the immune microenvironment, 2) driving macrophage conversion from pro-inflammatory M1 to anti-inflammatory and regenerative M2 phenotype, 3) granulation tissue formation by increasing fibroblast proliferation and promoting angiogenesis, and 4) supporting epithelialization.

Read more: Aurealis Therapeutics enters into 139 million USD agreement with Xbiome

The product candidate is currently being investigated in an ongoing international, randomized, placebo-controlled Phase-2 study that aims to evaluate the safety, tolerability, and efficacy of AUP-16 in non-healing neuro-ischemic diabetic foot ulcers.

Phase I study

The designation is based on positive data from completed Phase-1 study that was presented at the European Wound Management Association conference in May 2023. The results showed a dose-dependent improvement in wound closure, with the highest dose achieving 67% and 83% wound closure at 3 and 6 months respectively. According to EMA, the high rate of wound closure sufficiently demonstrates the potential of AUP-16 to address the unmet medical need in nhDFU to a significant extent.

Photo: iStock

Advertisement